Kane Biotech (KNE) AI Stock Analysis

• Market Cap: C$8.29M
• Dividend Yield: N/A
• Average Volume (3M): 133.49K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.17
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 165,771,560
• 10 Day Avg. Volume: 111,515
• 30 Day Avg. Volume: 133,487
• PEG Ratio: 0.13
• Price to Book (P/B): -18.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.18
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: C$0.00 ▼(-100.00%Downside)

Kane Biotech faces significant financial challenges, including negative margins, high leverage, and cash flow issues. While earnings call and corporate events indicate potential growth, these positives are overshadowed by the company's current financial instability and technical weakness.

Kane Biotech Business Overview & Revenue Model

Company Description

Kane Biotech (KNE) is a biotechnology company focused on developing and commercializing technologies and products that prevent and remove microbial biofilms. Operating primarily in the healthcare, animal health, and consumer goods sectors, the company's core offerings include innovative solutions targeting biofilm-related challenges. Kane Biotech's product portfolio features wound care and oral care products, as well as animal health solutions that leverage the company's expertise in biofilm disruption and management.

How the Company Makes Money

Kane Biotech generates revenue through the commercialization of its proprietary technologies and products designed to combat biofilms. The company's revenue streams include product sales, licensing agreements, and strategic partnerships. Kane Biotech sells its products directly to consumers and through distribution channels, targeting both the healthcare and animal health markets. Additionally, the company enters into licensing agreements with other entities to utilize its biofilm technologies, which provides a stream of royalty income. Strategic partnerships with other companies also contribute to Kane Biotech's earnings, enabling collaborative development and expanded market reach.

Kane Biotech Financial Statement Overview

Summary

Kane Biotech is facing significant financial challenges with declining revenues, negative profit margins, and a weak balance sheet due to negative equity. Cash flow issues persist with negative operating cash flow and reliance on external financing.

Income Statement

The income statement shows a significant decline in revenues over the recent periods, with the TTM (Trailing-Twelve-Months) revenue decreasing compared to the previous periods. Gross profit margins are negative, indicating cost of goods sold exceeds revenues. Net profit margins are also negative despite a positive net income due to extraordinary items. EBIT and EBITDA margins are significantly negative, highlighting operating challenges.

Balance Sheet

The balance sheet indicates a negative equity position, suggesting liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, but high total debt levels indicate high leverage. The equity ratio is negative, reflecting financial instability and potential insolvency risks.

Cash Flow

Cash flows are under pressure with negative operating cash flow and consistent negative free cash flow, indicating cash outflows exceed inflows from operations. The company relies heavily on financing activities, as indicated by substantial financing cash inflows in previous periods. However, recent periods show negative financing cash flow, reducing cash reserves.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
1.32M	148.98K	2.67M	1.61M	1.34M	1.69M
	Gross Profit
-103.46K	109.47K	1.41M	568.44K	526.86K	609.91K
	EBIT
-3.98M	-3.36M	-3.36M	-4.88M	-4.22M	-3.59M
	EBITDA
-3.85M	-3.23M	-2.95M	-4.25M	-3.65M	-764.08K
	Net Income Common Stockholders
5.60M	-5.03M	-3.89M	-4.60M	-3.72M	-960.18K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
568.25K	749.25K	1.10M	1.15M	1.01M	834.13K
	Total Assets
1.68M	5.68M	5.62M	6.13M	5.04M	2.76M
	Total Debt
0.00	9.26M	6.86M	4.71M	2.25M	169.81K
	Net Debt
-568.25K	8.51M	5.75M	3.56M	1.24M	-664.31K
	Total Liabilities
69.93K	14.09M	9.76M	7.70M	3.96M	1.92M
	Stockholders Equity
1.61M	-10.56M	-6.52M	-3.89M	-1.49M	836.81K
Cash Flow		Free Cash Flow
-5.67M	-3.23M	-3.13M	-2.64M	-4.07M	-1.05M
	Operating Cash Flow
-5.62M	-3.22M	-3.04M	-2.29M	-3.94M	-955.37K
	Investing Cash Flow
9.01M	-116.14K	-107.55K	-373.55K	-166.11K	-97.38K
	Financing Cash Flow
-5.61M	2.98M	3.10M	2.81M	4.28M	1.81M

Kane Biotech Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KNE, the sentiment is Negative. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, below the 50-day MA of 0.08, and below the 200-day MA of 0.11, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:KNE.

Kane Biotech Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.37B	3.35	-45.10%	2.79%	16.77%	-0.01%
KNE	45 Neutral	C$8.29M	―	-813.02%	―	―	―
BLAB	42 Neutral	C$9.74M	―	-175.45%	―	-3.93%	-575.24%
HEM	41 Neutral	C$17.44M	―	34.47%	―	―	43.45%
BETR	21 Underperform	C$14.55M	―	26.73%	―	―	-62.39%

Kane Biotech Corporate Events

Kane Biotech Reports Q1 2025 Results Amid Restructuring Efforts

Kane Biotech reported a significant increase in revenue for the first quarter of 2025, primarily from contract animal health manufacturing, despite a net loss. The company is undergoing a restructuring strategy to focus on its revyve™ product line and has implemented cost-reduction initiatives to strengthen its financial position. The departure of the CEO and subsequent legal action are notable developments, but the company remains committed to advancing its pipeline and creating long-term value for stakeholders.

Kane Biotech Secures $2.2 Million Through Private Placement and Insider Loan

Kane Biotech has successfully closed a private placement offering, raising $1.2 million through the issuance of 12 million shares to company insiders. Additionally, the company secured a $1 million unsecured loan from an insider, both transactions being classified as related party transactions. The funds will be used for working capital and general corporate purposes, potentially strengthening Kane Biotech’s financial position and operational capabilities.

Kane Biotech Reports 2024 Financials, Refocuses Strategy and Announces Leadership Change

Kane Biotech reported its financial results for the fourth quarter and full year 2024, showing a significant increase in revenue but a net loss for the year. The company is narrowing its strategic focus to its biofilm dispersion technology-based wound care products, particularly the revyve line, and is reorganizing its distribution approach in the U.S. market. A leadership change was also announced, with Dr. Robert Huizinga stepping in as interim CEO, following the departure of Marc Edwards.

Kane Biotech Revises Marketing Agreement with Outside the Box Capital

Kane Biotech has announced the termination of its previous service agreement with Outside the Box Capital Inc. (OTBC) and the initiation of a new agreement to enhance its marketing efforts within the financial community. This change was prompted by a policy update from the TSX Venture Exchange prohibiting the issuance of shares as compensation for investor relations services. Under the new agreement, OTBC will receive a cash payment and stock options, aligning with Kane Biotech’s strategic focus on broadening its media distribution and market awareness.

Kane Biotech Secures Approval for DispersinB® Acne Trial

Kane Biotech has received approval from the University of Miami Health System’s Internal Review Board to commence a clinical study of its DispersinB® Acne Cleanser for treating mild to moderate Acne Vulgaris. This trial, set to begin mid-year at the University of Miami Miller School of Medicine, marks a significant milestone for Kane Biotech as it continues to advance its mission of providing innovative dermatological solutions, potentially impacting millions of individuals suffering from acne.

Kane Biotech Partners with Best Buy Medical for Canadian Distribution of revyve™ Wound Gel

Kane Biotech has entered into a three-year distribution agreement with Best Buy Medical Canada for its revyve™ Antimicrobial Wound Gel, following Health Canada approval in November 2024. This strategic partnership aims to expand access to the wound care solution across Canada, targeting hospitals, clinics, and long-term care facilities. The collaboration is expected to enhance patient care and outcomes while tapping into the Canadian wound care market’s financial potential.